Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Drug Details

Click here to go back to your search results.

Brand Name: Doxil Trade Name: doxorubicin liposomal
FDA Approved For: 1. The treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. 2. The treatment of AIDS-related Kaposi’s sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. These indications are based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, such as improvement in disease-related symptoms or increased survival. Pediatric Use: The safety and effectiveness of Doxil® in pediatric patients have not been established.
Carcinogen: Secondary acute myelogenous leukemia has been reported in patients treated with topoisomerase II inhibitors, including anthracyclines. Although no studies have been conducted with Doxil®, doxorubicin HCl and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models. Mutagen: Although no studies have been conducted with Doxil®, doxorubicin HCl and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models.
Manufacturer and/or Distributor: Sequus Pharmaceuticals, Inc.    

Adverse Reactions:
For a complete list of adverse reactions please click on the link "More Information" for this drug.


E-mail to a Friend More Information

 

Disclaimer:This site provides excerpts from the product label or professional information brochures for some drugs or information provided by the World Health Organization’s International Agency for Research on Cancer. The full information from these sources is not provided by CancerMonthly. To view the full label or professional information brochure please contact the FDA. A link to the product label or professional information brochure is provided for your convenience, but CancerMonthly is not responsible for the availability of such external sites or resources. In addition, CancerMonthly does not provide medical or any other health care advice, diagnosis or treatment. The site and its services, including the information above, are for informational purposes only and are not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to existing treatment. Do not delay seeking and do not disregard medical advice based on information on this site. Cancer Monthly is solely to be used as an informational resource and should never be used to replace contact with your licensed healthcare provider.